Semaglutide-based weight loss drugs, such as Ozempic and Wegovy, are playing an increasingly important role in the treatment of obesity and type 2 diabetes, with demand for access to them on the NHS soaring.

But what role will these drugs have in tackling the obesity crisis, and what else should we be doing?

In University of Cambridge Stories article, Unit researchers Professor Jean Adams and Professor Martin White argue that we need to make eating well easier, to both help those who lose weight using medicines like semaglutide avoid regaining it, and to prevent obesity in the first place.

• Read the full story